Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
CPRXCatalyst Pharmaceuticals(CPRX) Zacks Investment Research·2024-05-10 00:41

Catalyst Pharmaceuticals, Inc. (CPRX) reported adjusted earnings of 38 cents per share for the first quarter of 2024, beating the Zacks Consensus Estimate of 34 cents. The company reported adjusted earnings of 41 cents in the year-ago quarter. Total revenues amounted to 98.5millioninthereportedquarter,whichsurpassedtheZacksConsensusEstimateof98.5 million in the reported quarter, which surpassed the Zacks Consensus Estimate of 97 million. Total product revenues climbed 15.4% to 98.4million,fromtheyearagoquarters98.4 million, from the year-ago quarter’s 85.3 million. The top line primarily comprised product sa ...